The Library
Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis : Results from the British Society for Rheumatology Biologics Registry
Tools
Brennan, A., Bansback, N., Nixon, R., Madan, Jason, Harrison, M., Watson, K. and Symmons, D. (2007) Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis : Results from the British Society for Rheumatology Biologics Registry. Rheumatology, 46 (8). 1345- 1354. doi:10.1093/rheumatology/kem115 ISSN 1462-0324.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: https://doi.org/10.1093/rheumatology/kem115
Abstract
Objective. To evaluate the cost effectiveness of TNF-α antagonist therapies for rheumatoid arthritis (RA) in the United Kingdom using data from the British Society for Rheumatology Biologics Registry (BSRBR). Methods. A simulation model is constructed to quantify the cost effectiveness of the TNF-α antagonist therapies (infliximab, etanercept and adalimumab) as a group versus traditional disease-modifying anti-rheumatic drugs, with a time horizon over the full patient lifetime. Participants are UK NHS patients in the BSRBR with RA who have failed at least two traditional disease-modifying anti-rheumatic drugs. The BSRBR aims to recruit all RA patients starting on a TNF-α antagonist agent and follows them 6 monthly via consultant and patient administered questionnaires. Data collected include disease activity scores (DAS28), the Health Assessment Questionnaire and the SF-36. Costs include drug, monitoring and hospitalisations. Benefits are measured in disability and quality of life improvements. The main outcome measure is the incremental cost per quality adjusted life-year gained (discounted). Results. The basecase cost per quality adjusted life-year gained by using TNF-α antagonist therapies is estimated at £23 882, with probabilistic uncertainty analysis suggesting that the probability that treatments are below £30 000 per QALY is around 84%. The results are most sensitive to assumptions concerning long-term disability progression, discount rates and the validity or otherwise of SF6D derived utility measures. Subgroup analysis, monotherapy versus combination with methotrexate, and a limited analysis of sequential therapy with two TNF-α antagonist agents, suggest cost-effectiveness ratios around £20 000 to £30 000. Conclusions. The BSRBR data provide valuable evidence for estimating cost-effectiveness. The analysis concludes that current policies and practice for the use of TNF-α antagonist therapies, after RA patients have failed at least two traditional disease-modifying anti-rheumatic drugs, appear cost-effective in the context of the NICE re-appraisal of 2006 for England and Wales, thus supporting their decision to continue their reimbursement. Decision-makers worldwide might adapt this analysis because differential costs, discount rates and other factors could affect results. There remains uncertainty, particularly on long-term disease progression. Further data collection using the BSRBR is recommended, together with a revision to this analysis when data become available. © The Author 2007.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Subjects: | R Medicine > R Medicine (General) | ||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Journal or Publication Title: | Rheumatology | ||||
Publisher: | Oxford University Press | ||||
ISSN: | 1462-0324 | ||||
Official Date: | 18 September 2007 | ||||
Dates: |
|
||||
Volume: | 46 | ||||
Number: | 8 | ||||
Page Range: | 1345- 1354 | ||||
DOI: | 10.1093/rheumatology/kem115 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access | ||||
Date of first compliant deposit: | 19 July 2018 | ||||
Funder: | Amgen, Abbott Laboratories, University of Manchester, British School at Rome, British Society for Rheumatology, Metropolitan Museum of Art, University of Sheffield | ||||
Grant number: | 10000 |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |